medigraphic.com
ISSN 0035-0052 (Print)

2026, Number 3

<< Back Next >>

Rev Mex Pediatr 2026; 93 (3)

Frequency of hemoglobinopathies in patients with anemia at a pediatric hospital in Mexico

López Guerrero-González D, Sandoval-Cabrera A, Santillán-Benítez JG, Reyes-Gutiérrez FM, Contreras-Huerta S

Language: Spanish
References: 15
Page: 102-108
PDF size: 1141.12 Kb.


ABSTRACT

Introduction: hemoglobinopathies constitute a group of hereditary hemoglobin disorders with variable clinical impact on the pediatric population, depending on their specific characteristics and the severity of clinical manifestations. In Mexico, these diseases pose a diagnostic challenge due to limited access to identification technologies. Objective: to describe the frequency of hemoglobinopathies in pediatric patients with anemia treated at a pediatric hospital in the State of Mexico, using a diagnostic protocol based on screening tests and electrophoresis. Material and methods: blood samples were evaluated via complete blood count and classified into two groups: microcytic hypochromic anemia (MHA) and normocytic normochromic anemia (NNA). All samples underwent sickling induction tests, hemoglobin H inclusion tests, and hemoglobin electrophoresis. Results: ninety patients aged eight months to 16 years were included. Of the total, 53.3% were classified as having NNA and 46.6% as having MHA. The prevalence of hemoglobinopathies was 5.5%, with two cases of alphathalassemia, two of beta-thalassemia, and one of sickle cell anemia observed. Conclusions: the implementation of a sequential diagnostic protocol identified a 5.5% prevalence of hemoglobinopathies.


REFERENCES

  1. Harteveld CL, Achour A, Arkesteijn SJG et al. Hemoglobinopathies:molecular disease mechanisms and diagnostics. Int J Lab Hematol. 2022; 44(Suppl 1): 28-36. doi: 10.1111/ijlh.13885.

  2. Jiménez-Cobo C, Sebastián-Pérez E, Sevilla-Navarro J.Hemoglobinopatías: talasemia y drepanocitosis. Pediatr Integral.2021; 25(5): 241.e1-241.e13.

  3. Saunthararajah Y. β-hemoglobinopathies lead the way. Blood.2021; 137(12): 1567-1569. doi: 10.1182/blood.2020009961.

  4. Royo DC, Martínez SV. Protocolo diagnóstico de las anemiasmicrocíticas, normocíticas y macrocíticas. Medicine-Programa deFormación Médica Continuada Acreditado. 2020; 13(21): 1216-1219. Disponible en: https://doi.org/10.1016/j.med.2020.11.015

  5. Mora D, Rodríguez A, Montes A, Borunda J et al. Biologíamolecular: fundamentos y aplicaciones en las ciencias de la salud.2a ed. México: McGraw-Hill; 2016.

  6. The Lancet Global Health. Homing in on haemoglobinopathies.Lancet Glob Health. 2022; 10(1): e1. doi: 10.1016/S2214-109X(21)00559-3.

  7. Wollenstein-Seligson D, Rendón-Macías ME, Silva-RamírezH, et al. Prevalencia al nacimiento de hemoglobinopatíasen un hospital privado de la Ciudad de México: reporte de 7años de tamizaje. Rev Mex Pediatr. 2023; 90(6): 232-235. doi:10.35366/117391.

  8. Hernández-Verdugo LY, Fernández-Bautista MF, Domínguez-Camacho A et al. Prevalencia de anemias hemolíticas hereditariasdetectadas por tamiz metabólico ampliado en los servicios de saludde Petróleos Mexicanos. Rev Mex Pediatr. 2023; 90(2): 57-62. doi:10.35366/113266.

  9. Bain BJ, Bates I, Laffan MA. Dacie and Lewis practicalhaematology. 11th ed. Philadelphia: Elsevier; 2018.

  10. Zago MA, Costa FF, Tone LG, Bottura C. Hereditary hemoglobindisorders in a Brazilian population. Hum Hered. 1983; 33(2): 125-129. doi: 10.1159/000153362.

  11. Williams TN, Weatherall DJ. World distribution, populationgenetics, and health burden of the hemoglobinopathies. ColdSpring Harb Perspect Med. 2012; 2(9): a011692. doi: 10.1101/cshperspect.a011692.

  12. Schipper A, Rutten M, van Gammeren A, et al. Machine learning-basedprediction of hemoglobinopathies using complete blood count data.Clin Chem. 2024; 70(8): 1064-1075. doi: 10.1093/clinchem/hvae081.

  13. Goonasekera HW, Paththinige CS, Dissanayake VH. Populationscreening for hemoglobinopathies. Annu Rev GenomicsHum Genet. 2018; 19:355-380. doi: 10.1146/annurevgenom-091416-035451.

  14. Diamantidis MD, Ikonomou G, Argyrakouli I, et al. Geneticmodifiers of hemoglobin expression from a clinical perspectivein hemoglobinopathy patients with beta thalassemia and sicklecell disease. Int J Mol Sci. 2024; 25(22): 11886. doi: 10.3390/ijms252211886.

  15. Echeverría UM, López DAI, Oliveros CR, Álvarez ND. Diagnósticode hemoglobinopatías en el laboratorio clínico: hallazgo de unahemoglobina hofu oculta en HPLC. Adv Lab Med. 2025; 6(2):217-220. doi: 10.1515/almed-2024-0081.




2020     |     www.medigraphic.com